The effectiveness of Vonoprazan comparing with high dose proton pump inhibitor in recurrence bleeding rate of high risk peptic ulcer: A randomised controlled study

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210227002

Enrollment

100

Registered

2021-02-27

Start date

2021-02-26

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bleeding peptic ulcer Proton pump inhibitor, Potassium competitive acid blocker, Peptic ulcer disease, Upper gastrointestinal bleeding, Vonoprazan, Mortality, Rebleeding

Interventions

After endoscopic homeostasis is achieved, An intravenous proton pump inhibitor is given for 72 hours then oral Omeprazole 20 mg twice daily is prescribed for 2 weeks then switch to once-daily dose for

Active Comparator Drug,Experimental Drug

Intravenous proton pump inhibitor,Vonoprazan 20 mg oral twice daily

Eligibility

Sex/Gender

All

Age

15 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Age 15-70 years old 2.Bleeding peptic ulcer which is achieved hemostasis by the endoscopic intervention(if adrenaline injection is used combination therapy should be applied) 3.Feeding via oral 4.No active malignancy

Exclusion criteria

Exclusion criteria: 1.Not achieve hemostasis by the endoscopic intervention 2.Pregnancy and lactation 3.Patient who receives protease inhibitor 4.Advanced cirrhosis CTP C 5.Patient with active cardiovascular disease

Design outcomes

Primary

Measure	Time frame
Rebleeding rate 72 hours Rebleeding rate	—

Secondary

Measure	Time frame
28-day mortality 28 days 28-day mortality	—

Countries

Thailand

Contacts

Public ContactTanawat Pattarapantakul

NKC institute, Songklanakarind hospital

Tanawat_kuey@hotmail.com0979655195

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026